A study of effect of carvedilol on serum creatine kinase- MB and troponin I levels in doxorubicin treated females with breast cancer

Abstract

Background: Doxorubicin based regimen is the most common treatment of breast cancer which is highly complicated by cardiotoxicity.Aim: To clarify the possible effects of carvedilol on serum CK-MB and Troponin I in doxorubicin based regimen in females with breast cancer.Patients and Methods: A total of 16 females with breast cancer were included in this study. The patients were randomized into 2 groups , 8 patients each. Group I included patients were treated with doxorubicin based regimen for 6 cycles with 21 day apart. Group II included patients were received doxorubicin based regimen with carvedilol 3.125 mg , orally , twice daily for 5 days , for 6 cycles. Serum CK-MB and Troponin I were measured at zero time and 3 days after 2nd, 4th and 6th cycles in both groups.Results: The following results were obtained:1- Treatment with doxorubicin based regimen caused highly significant elevation in serum CK-MB and Troponin levels after 2nd, 4th and 6th cycles in comparison to baseline readings (P < 0.01).2- Combined CAF + Carvedilol 3.125 mg orally twice daily for 5 days caused highly significant decrement in serum CK-MB and Troponin I levels compared with that of doxorubicin based regimen group (P < 0.01).Conclusion: From the present study , we can conclude that Carvedilol causes highly significant decrease in serum CK-MB and Troponin I levels in doxorubicin treated patients.